Alpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2023
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
Highlights
The global Alpha 1 Antitrypsin Deficiency Treatment market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alpha 1 Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha 1 Antitrypsin Deficiency Treatment.
The Alpha 1 Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Alpha 1 Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha 1 Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Global markets are presented by Alpha 1 Antitrypsin Deficiency Treatment type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Alpha 1 Antitrypsin Deficiency Treatment are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Alpha 1 Antitrypsin Deficiency Treatment segment by Indication
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Alpha 1 Antitrypsin Deficiency Treatment market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Alpha 1 Antitrypsin Deficiency Treatment market.
Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Alpha 1 Antitrypsin Deficiency Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Alpha 1 Antitrypsin Deficiency Treatment industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Highlights
The global Alpha 1 Antitrypsin Deficiency Treatment market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Alpha 1 Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha 1 Antitrypsin Deficiency Treatment.
The Alpha 1 Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Alpha 1 Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha 1 Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Takeda
- Baxter
- Grifols
- CSL Behring
- Kamada Ltd
- Chiesi Pharmaceuticals
- Kedrion Group
- Vertex Pharmaceuticals
- ProMetic Life Sciences
Global markets are presented by Alpha 1 Antitrypsin Deficiency Treatment type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Alpha 1 Antitrypsin Deficiency Treatment are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Alpha 1 Antitrypsin Deficiency Treatment segment by Indication
- Augmentation Therapy
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Diabetes
- Other
This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Alpha 1 Antitrypsin Deficiency Treatment market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Alpha 1 Antitrypsin Deficiency Treatment market.
Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users
- COPD
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Diabetes
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Alpha 1 Antitrypsin Deficiency Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Alpha 1 Antitrypsin Deficiency Treatment industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Alpha 1 Antitrypsin Deficiency Treatment by Indication
2.2.1 Market Value Comparison by Indication (2018 VS 2022 VS 2029)
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
2.3 Alpha 1 Antitrypsin Deficiency Treatment by End Users
2.3.1 Market Value Comparison by End Users (2018 VS 2022 VS 2029)
2.3.2 COPD
2.3.3 Cystic Fibrosis(CF)
2.3.4 Non-CF Bronchiectasis(NCFB)
2.3.5 Diabetes
2.4 Assumptions and Limitations
3 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY INDICATION
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2018-2023)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)
4 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY END USERS
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2018-2023)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2018-2029)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2018-2023)
5.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029)
5.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
5.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
5.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
5.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
5.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
6.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2018-2023)
6.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2018-2023)
6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment Head office and Area Served
6.4 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
6.5 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Date of Enter into This Industry
6.6 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
7.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
7.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
8.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
8.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
9.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
9.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
10.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
10.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
11.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
11.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.14.5 ProMetic Life Sciences Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Alpha 1 Antitrypsin Deficiency Treatment by Indication
2.2.1 Market Value Comparison by Indication (2018 VS 2022 VS 2029)
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
2.3 Alpha 1 Antitrypsin Deficiency Treatment by End Users
2.3.1 Market Value Comparison by End Users (2018 VS 2022 VS 2029)
2.3.2 COPD
2.3.3 Cystic Fibrosis(CF)
2.3.4 Non-CF Bronchiectasis(NCFB)
2.3.5 Diabetes
2.4 Assumptions and Limitations
3 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY INDICATION
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2018-2023)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2023-2028)
4 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT BREAKDOWN DATA BY END USERS
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2018-2023)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2018-2023)
5 GLOBAL GROWTH TRENDS
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2018-2029)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
5.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2018-2023)
5.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029)
5.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
5.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
5.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
5.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
5.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
6.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2018-2023)
6.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2018-2023)
6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment Head office and Area Served
6.4 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
6.5 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Date of Enter into This Industry
6.6 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
7.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
7.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 EUROPE
8.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
8.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
8.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
9.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
9.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 LATIN AMERICA
10.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
10.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
10.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
11.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
11.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 PLAYERS PROFILED
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022)
11.14.5 ProMetic Life Sciences Recent Development
13 REPORT CONCLUSION
14 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Indication (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by End Users (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2018-2023) & (US$ Million)
Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2018-2023)
Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2024-2029) & (US$ Million)
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2024-2029)
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2018-2023) & (US$ Million)
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2018-2023)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2024-2029) & (US$ Million)
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2024-2029)
Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2018-2023)
Table 16. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2024-2029)
Table 18. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 19. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 20. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 21. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 22. Global Top Alpha 1 Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Headquarters and Area Served
Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 45. Pfizer Company Detail
Table 46. Pfizer Business Overview
Table 47. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 48. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 49. Pfizer Recent Development
Table 50. GlaxoSmithKline Company Detail
Table 51. GlaxoSmithKline Business Overview
Table 52. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 53. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 54. GlaxoSmithKline Recent Development
Table 55. AstraZeneca Company Detail
Table 56. AstraZeneca Business Overview
Table 57. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 58. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 59. AstraZeneca Recent Development
Table 60. Boehringer Ingelheim Company Detail
Table 61. Boehringer Ingelheim Business Overview
Table 62. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 63. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 64. Boehringer Ingelheim Recent Development
Table 65. Teva Pharmaceutical Industries Company Detail
Table 66. Teva Pharmaceutical Industries Business Overview
Table 67. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 68. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 69. Teva Pharmaceutical Industries Recent Development
Table 70. Takeda Company Detail
Table 71. Takeda Business Overview
Table 72. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 73. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 74. Takeda Recent Development
Table 75. Baxter Company Detail
Table 76. Baxter Business Overview
Table 77. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 78. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 79. Baxter Recent Development
Table 80. Grifols Company Detail
Table 81. Grifols Business Overview
Table 82. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 83. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 84. Grifols Recent Development
Table 85. CSL Behring Company Detail
Table 86. CSL Behring Business Overview
Table 87. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 88. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 89. CSL Behring Recent Development
Table 90. Kamada Ltd Company Detail
Table 91. Kamada Ltd Business Overview
Table 92. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 93. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 94. Kamada Ltd Recent Development
Table 95. Chiesi Pharmaceuticals Company Detail
Table 96. Chiesi Pharmaceuticals Business Overview
Table 97. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 98. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 99. Chiesi Pharmaceuticals Recent Development
Table 100. Kedrion Group Company Detail
Table 101. Kedrion Group Business Overview
Table 102. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 103. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 104. Kedrion Group Recent Development
Table 105. Vertex Pharmaceuticals Company Detail
Table 106. Vertex Pharmaceuticals Business Overview
Table 107. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 108. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 109. Vertex Pharmaceuticals Recent Development
Table 110. ProMetic Life Sciences Company Detail
Table 111. ProMetic Life Sciences Business Overview
Table 112. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 113. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 114. ProMetic Life Sciences Recent Development
Table 115. Pfizer Company Information
Table 116. Pfizer Business Overview
Table 117. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 118. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 119. Pfizer Recent Development
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Business Overview
Table 122. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 123. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 124. GlaxoSmithKline Recent Development
Table 125. AstraZeneca Company Information
Table 126. AstraZeneca Business Overview
Table 127. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 128. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 129. AstraZeneca Recent Development
Table 130. Boehringer Ingelheim Company Information
Table 131. Boehringer Ingelheim Business Overview
Table 132. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 133. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 134. Boehringer Ingelheim Recent Development
Table 135. Teva Pharmaceutical Industries Company Information
Table 136. Teva Pharmaceutical Industries Business Overview
Table 137. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 138. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 139. Teva Pharmaceutical Industries Recent Development
Table 140. Takeda Company Information
Table 141. Takeda Business Overview
Table 142. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 143. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 144. Takeda Recent Development
Table 145. Baxter Company Information
Table 146. Baxter Business Overview
Table 147. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 148. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 149. Baxter Recent Development
Table 150. Grifols Company Information
Table 151. Grifols Business Overview
Table 152. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 153. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 154. Grifols Recent Development
Table 155. CSL Behring Company Information
Table 156. CSL Behring Business Overview
Table 157. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 158. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 159. CSL Behring Recent Development
Table 160. Kamada Ltd Company Information
Table 161. Kamada Ltd Business Overview
Table 162. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 163. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 164. Kamada Ltd Recent Development
Table 165. Chiesi Pharmaceuticals Company Information
Table 166. Chiesi Pharmaceuticals Business Overview
Table 167. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 168. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 169. Chiesi Pharmaceuticals Recent Development
Table 170. Kedrion Group Company Information
Table 171. Kedrion Group Business Overview
Table 172. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 173. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 174. Kedrion Group Recent Development
Table 175. Vertex Pharmaceuticals Company Information
Table 176. Vertex Pharmaceuticals Business Overview
Table 177. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 178. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 179. Vertex Pharmaceuticals Recent Development
Table 180. ProMetic Life Sciences Company Information
Table 181. ProMetic Life Sciences Business Overview
Table 182. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 183. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 184. ProMetic Life Sciences Recent Development
Table 185. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Indication (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by End Users (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2018-2023) & (US$ Million)
Table 6. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2018-2023)
Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2024-2029) & (US$ Million)
Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2024-2029)
Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2018-2023) & (US$ Million)
Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2018-2023)
Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2024-2029) & (US$ Million)
Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2024-2029)
Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2018-2023)
Table 16. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2024-2029)
Table 18. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
Table 19. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
Table 20. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
Table 21. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
Table 22. Global Top Alpha 1 Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Alpha 1 Antitrypsin Deficiency Treatment, Headquarters and Area Served
Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 45. Pfizer Company Detail
Table 46. Pfizer Business Overview
Table 47. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
Table 48. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 49. Pfizer Recent Development
Table 50. GlaxoSmithKline Company Detail
Table 51. GlaxoSmithKline Business Overview
Table 52. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
Table 53. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 54. GlaxoSmithKline Recent Development
Table 55. AstraZeneca Company Detail
Table 56. AstraZeneca Business Overview
Table 57. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
Table 58. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 59. AstraZeneca Recent Development
Table 60. Boehringer Ingelheim Company Detail
Table 61. Boehringer Ingelheim Business Overview
Table 62. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
Table 63. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 64. Boehringer Ingelheim Recent Development
Table 65. Teva Pharmaceutical Industries Company Detail
Table 66. Teva Pharmaceutical Industries Business Overview
Table 67. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
Table 68. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 69. Teva Pharmaceutical Industries Recent Development
Table 70. Takeda Company Detail
Table 71. Takeda Business Overview
Table 72. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
Table 73. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 74. Takeda Recent Development
Table 75. Baxter Company Detail
Table 76. Baxter Business Overview
Table 77. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
Table 78. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 79. Baxter Recent Development
Table 80. Grifols Company Detail
Table 81. Grifols Business Overview
Table 82. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
Table 83. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 84. Grifols Recent Development
Table 85. CSL Behring Company Detail
Table 86. CSL Behring Business Overview
Table 87. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
Table 88. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 89. CSL Behring Recent Development
Table 90. Kamada Ltd Company Detail
Table 91. Kamada Ltd Business Overview
Table 92. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
Table 93. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 94. Kamada Ltd Recent Development
Table 95. Chiesi Pharmaceuticals Company Detail
Table 96. Chiesi Pharmaceuticals Business Overview
Table 97. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 98. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 99. Chiesi Pharmaceuticals Recent Development
Table 100. Kedrion Group Company Detail
Table 101. Kedrion Group Business Overview
Table 102. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 103. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 104. Kedrion Group Recent Development
Table 105. Vertex Pharmaceuticals Company Detail
Table 106. Vertex Pharmaceuticals Business Overview
Table 107. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 108. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 109. Vertex Pharmaceuticals Recent Development
Table 110. ProMetic Life Sciences Company Detail
Table 111. ProMetic Life Sciences Business Overview
Table 112. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentProduct
Table 113. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
Table 114. ProMetic Life Sciences Recent Development
Table 115. Pfizer Company Information
Table 116. Pfizer Business Overview
Table 117. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 118. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 119. Pfizer Recent Development
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Business Overview
Table 122. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 123. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 124. GlaxoSmithKline Recent Development
Table 125. AstraZeneca Company Information
Table 126. AstraZeneca Business Overview
Table 127. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 128. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 129. AstraZeneca Recent Development
Table 130. Boehringer Ingelheim Company Information
Table 131. Boehringer Ingelheim Business Overview
Table 132. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 133. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 134. Boehringer Ingelheim Recent Development
Table 135. Teva Pharmaceutical Industries Company Information
Table 136. Teva Pharmaceutical Industries Business Overview
Table 137. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 138. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 139. Teva Pharmaceutical Industries Recent Development
Table 140. Takeda Company Information
Table 141. Takeda Business Overview
Table 142. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 143. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 144. Takeda Recent Development
Table 145. Baxter Company Information
Table 146. Baxter Business Overview
Table 147. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 148. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 149. Baxter Recent Development
Table 150. Grifols Company Information
Table 151. Grifols Business Overview
Table 152. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 153. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 154. Grifols Recent Development
Table 155. CSL Behring Company Information
Table 156. CSL Behring Business Overview
Table 157. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 158. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 159. CSL Behring Recent Development
Table 160. Kamada Ltd Company Information
Table 161. Kamada Ltd Business Overview
Table 162. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 163. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 164. Kamada Ltd Recent Development
Table 165. Chiesi Pharmaceuticals Company Information
Table 166. Chiesi Pharmaceuticals Business Overview
Table 167. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 168. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 169. Chiesi Pharmaceuticals Recent Development
Table 170. Kedrion Group Company Information
Table 171. Kedrion Group Business Overview
Table 172. Kedrion Group Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 173. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 174. Kedrion Group Recent Development
Table 175. Vertex Pharmaceuticals Company Information
Table 176. Vertex Pharmaceuticals Business Overview
Table 177. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 178. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 179. Vertex Pharmaceuticals Recent Development
Table 180. ProMetic Life Sciences Company Information
Table 181. ProMetic Life Sciences Business Overview
Table 182. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency TreatmentRevenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
Table 183. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million) Portfolio
Table 184. ProMetic Life Sciences Recent Development
Table 185. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Alpha 1 Antitrypsin Deficiency Treatment Product Picture
Figure 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by Indication (2023-2029) & (US$ Million)
Figure 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2022 VS 2029
Figure 7. Augmentation Therapy Product Picture
Figure 8. Cystic Fibrosis(CF) Product Picture
Figure 9. Non-CF Bronchiectasis(NCFB) Product Picture
Figure 10. Diabetes Product Picture
Figure 11. Other Product Picture
Figure 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2029) & (US$ Million)
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2022 VS 2029
Figure 14. COPD Product Picture
Figure 15. Cystic Fibrosis(CF) Product Picture
Figure 16. Non-CF Bronchiectasis(NCFB) Product Picture
Figure 17. Diabetes Product Picture
Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2022 VS 2029
Figure 21. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2022
Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Players, Date of Enter into This Industry
Figure 23. Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2022
Figure 24. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 25. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 27. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 31. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 47. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 51. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 56. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 57. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 58. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 59. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 60. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 61. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 62. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 63. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 64. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 65. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 66. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 67. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Alpha 1 Antitrypsin Deficiency Treatment Product Picture
Figure 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by Indication (2023-2029) & (US$ Million)
Figure 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2022 VS 2029
Figure 7. Augmentation Therapy Product Picture
Figure 8. Cystic Fibrosis(CF) Product Picture
Figure 9. Non-CF Bronchiectasis(NCFB) Product Picture
Figure 10. Diabetes Product Picture
Figure 11. Other Product Picture
Figure 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2023-2029) & (US$ Million)
Figure 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2022 VS 2029
Figure 14. COPD Product Picture
Figure 15. Cystic Fibrosis(CF) Product Picture
Figure 16. Non-CF Bronchiectasis(NCFB) Product Picture
Figure 17. Diabetes Product Picture
Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2022 VS 2029
Figure 21. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2022
Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Players, Date of Enter into This Industry
Figure 23. Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2022
Figure 24. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 25. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 27. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 31. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 39. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 47. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
Figure 51. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 56. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 57. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 58. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 59. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 60. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 61. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 62. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 63. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 64. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 65. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 66. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
Figure 67. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
